Information About the Peachtree Uveitis Study

The Peachtree study, conducted by Clearside Biomedical, enrolled 160 patients with macular edema associated with non-infectious uveitis. Patients were randomized to receive two unilateral suprachoroidal CLS-TA injections or two unilateral suprachoroidal sham procedures approximately 12 weeks apart. 

The study’s goal was to measure the proportion of patients with a change from baseline of at least 15 letters in base corrected visual acuity at 24 weeks.

The study began in November of 2015, and is expected to complete in February of 2018. 

Learn More About the Study

• ClinicalTrials.gov
  You can learn more about the Peachtree Uveitis study, “Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis” – identifier NCT02595398, from the ClinicalTrials.gov website. 
• Clearside Biomedical
  On March 03, 2015, Clearside Biomedical issued a press release with information about the Peachtree study’s preliminary results.  

Our Connection With The Uveitis Study

Moscow Family Eye Care IS NOT connected with the Peachtree study, or Clearside Biomedical, Inc.  The study’s founders have not maintained its original website, and we are providing this information as a resource to our patients, and anyone else interested in the study.